Core Viewpoint - Eupraxia Pharmaceuticals has successfully closed a public offering of 14,636,363 common shares at a price of US$5.50 per share, raising approximately US$80.5 million in gross proceeds, which will be used to advance its product pipeline and support key clinical and regulatory milestones [1][2][3] Group 1: Offering Details - The public offering included the full exercise of the underwriters' option to purchase additional shares [1] - The offering was conducted under a U.S. registration statement declared effective by the SEC and the existing Canadian short form base shelf prospectus [4] Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund the advancement of the product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and commercial preparation [3] - Additional allocations will support research and development of new pipeline candidates, business development initiatives, and general corporate purposes [3] Group 3: Company Background - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products to address high unmet medical needs [7] - The company utilizes its proprietary Diffusphere™ technology for optimized local drug delivery [7]